New drug aims to tame overactive thyroid in Graves' disease
NCT ID NCT07661056
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 20 times
Summary
This study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels at 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BHV-1300
- What this could lead to
- If successful, BHV-1300 could offer a new treatment option for Graves' disease that helps patients achieve normal thyroid function without needing antithyroid drugs.
- What could go wrong
- This is an early phase 3 trial, so results may not confirm benefit. The drug may cause side effects or fail to outperform placebo. Long-term safety and efficacy are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Site-006
RECRUITINGSan Diego, California, 92108, United States
-
Site-008
RECRUITINGCanton, Ohio, 44718, United States
-
Site-011
RECRUITINGGreenville, North Carolina, 27834, United States
-
Site-013
RECRUITINGLayton, Utah, 84041, United States
-
Site-016
RECRUITINGChattanooga, Tennessee, 37411, United States
-
Site-019
RECRUITINGHialeah, Florida, 33016, United States
-
Site-020
RECRUITINGDallas, Texas, 75246, United States
-
Site-025
RECRUITINGLenexa, Kansas, 66234, United States
-
Site-031
RECRUITINGChampaign, Illinois, 61822, United States
-
Site-032
RECRUITINGBurbank, California, 91501, United States
-
Site-033
RECRUITINGStatesville, North Carolina, 28625, United States
-
Site-036
RECRUITINGShavano Park, Texas, 78231, United States
-
Site-038
RECRUITINGAsheville, North Carolina, 28803, United States
-
Site-039
RECRUITINGRaleigh, North Carolina, 27612, United States
-
Site-042
RECRUITINGEl Paso, Texas, 79935, United States
-
Site-043
RECRUITINGDenton, Texas, 76210, United States
-
Site-045
RECRUITINGWilmington, North Carolina, 28405, United States
-
Site-046
RECRUITINGFarmington Hills, Michigan, 48334, United States
-
Site-052
RECRUITINGDoral, Florida, 33172, United States
-
Site-054
RECRUITINGMcKinney, Texas, 75069, United States
-
Site-055
RECRUITINGDallas, Texas, 75231, United States
-
Site-057
RECRUITINGSan Antonio, Texas, 78251, United States
-
Site-062
RECRUITINGHuntington Beach, California, 92647, United States
-
Site-063
RECRUITINGMorehead City, North Carolina, 28557, United States
-
Site-064
RECRUITINGMorehead City, North Carolina, 28557, United States
-
Site-067
RECRUITINGWalnut Creek, California, 94598, United States
-
Site-071
RECRUITINGHouston, Texas, 77058, United States
-
Site-072
RECRUITINGLas Vegas, Nevada, 89148, United States
-
Site-073
RECRUITINGMidlothian, Virginia, 23112, United States
-
Site-076
RECRUITINGSeattle, Washington, 98104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can a steroid shot make thyroid surgery safer?
- Targeting the immune system: a new antibody may free Graves' patients from daily drugs
- AI reads eye scans to spot thyroid disease activity and severity
- New drug aims to tame overactive thyroid in Graves' disease
- Smartwatch AI could spot dangerous thyroid Flare-Ups